Black Diamond Valuation
| BDTX Stock | USD 2.51 0.03 1.18% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Black Diamond Therap shows a prevailing Real Value of $4.69 per share. The current price of the firm is $2.51. Our model approximates the value of Black Diamond Therap from analyzing the firm fundamentals such as current valuation of 54.04 M, and Return On Equity of -0.63 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Black Diamond's valuation include:
Price Book 1.4752 | Enterprise Value 54 M | Enterprise Value Ebitda (1.92) |
Undervalued
Today
Please note that Black Diamond's price fluctuation is relatively risky at this time. Calculation of the real value of Black Diamond Therap is based on 3 months time horizon. Increasing Black Diamond's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Black Diamond is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Black Stock. However, Black Diamond's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.51 | Real 4.69 | Target 11.33 | Hype 2.76 | Naive 2.23 |
The intrinsic value of Black Diamond's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Black Diamond's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Black Diamond Therapeutics helps investors to forecast how Black stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Black Diamond more accurately as focusing exclusively on Black Diamond's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Black Diamond's intrinsic value based on its ongoing forecasts of Black Diamond's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Black Diamond's closest peers.
Black Diamond Cash |
|
Black Valuation Trend
Analysing the historical paterns of Black Diamond's enterprise value and its market capitalization is a good way to estimate and gauge the value of Black Diamond Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Black Diamond Total Value Analysis
Black Diamond Therapeutics is currently anticipated to have valuation of 54.04 M with market capitalization of 143.73 M, debt of 25.3 M, and cash on hands of 160.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Black Diamond fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
54.04 M | 143.73 M | 25.3 M | 160.89 M |
Black Diamond Asset Utilization
One of the ways to look at asset utilization of Black is to check how much profit was generated for every dollar of assets it reports. Black Diamond Therapeutics shows a negative utilization of assets of -0.33 percent, losing $0.003278 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Black Diamond Therapeutics shows how unproductive it operates for each dollar spent on its assets.Black Diamond Ownership Allocation
Black Diamond holds a total of 56.59 Million outstanding shares. The majority of Black Diamond Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Black Diamond Therap to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Black Diamond. Please pay attention to any change in the institutional holdings of Black Diamond Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that nearly seven hundred seven thousand three hundred fourteen invesors are currently shorting Black Diamond expressing very little confidence in its future performance.Black Diamond Profitability Analysis
Net Loss for the year was (82.44 M) with profit before overhead, payroll, taxes, and interest of 0.About Black Diamond Valuation
Our relative valuation model uses a comparative analysis of Black Diamond. We calculate exposure to Black Diamond's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Black Diamond's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -437 K | -458.9 K |
Black Diamond Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 44 M |
Black Diamond Current Valuation Indicators
Valuation refers to the process of determining the present value of Black Diamond Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Black we look at many different elements of the entity such as Black's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Black Diamond, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Black Diamond's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Black Diamond's worth.Additional Tools for Black Stock Analysis
When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.